Clinical Study of OR for Second-line Treatment of Refractory MZL
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.
OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
DRUG: Orelabrutinib combined with rituximab
Objective Response Rate, Proportion of CR and PR subjects will be assessed at 8 courses, up to 8 months
Progress free survival time, To measure the duration of response over a follow-up period of 36 months, up to36 months|Overall survival, OS will be assessed from the first receptor given to death or last follow-up., up to36 months|Adverse events profile, Number of participants with adverse events. Frequencies of toxicities based on the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 will be tabulated., Measured from start of treatment until 21 days after last dose
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.